Background-We aimed to develop a multivariable statistical model for risk stratification in patients with chronic heart failure with systolic dysfunction, using patient data that are routinely collected and easily obtained at the time of initial presentation.
D espite advances in the treatment of patients with chronic heart failure (HF) with systolic dysfunction, these patients remain at high risk for hospitalization and death. 1 This risk may be attributed to the aging of the population, progressive disease, increasing frequency of HF hospitalizations, and persistently high event rates after decompensated HF episodes, with up to 30% of patients experiencing a serious adverse cardiovascular event or death after a hospital admission for HF. 2 
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Timing for the introduction of second-line therapies, including aldosterone antagonists, resynchronization pacing, left ventricular assist devices, or cardiac transplantation, often is based on an assessment of patient risk. A risk assessment algorithm ideally should integrate all clinically relevant, validated, and appropriately weighted variables; further, these variables should be easy to obtain from a broad cohort of patients with HF in typical clinical settings. Previous attempts to develop such risk models have achieved varying degrees of success. [3] [4] [5] [6] [7] [8] [9] [10] [11] Importantly, most models (including The Seattle Heart Failure Model) were developed before modern evidence-based therapies and performance measures were broadly applied. 12 The recently completed Heart Failure: A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) trial 13 included 2331 well-characterized ambulatory patients with HF. Study participants received guideline-based therapies and were systematically followed with standardized assessments of clinical outcomes that included the primary composite end point of death or hospitalization from any cause and the secondary end point of death alone. We used this robust database to develop a predictive risk model for these end points from easily obtainable clinical patient characteristics and laboratory data. We also developed a simple point-based risk score to facilitate ease of use in clinical practice for identifying patients with HF who are at higher risk for morbidity and mortality.
Methods

Patient Cohort
The HF-ACTION trial design and outcomes have been previously described. 13 Briefly, the study was a multicenter randomized controlled trial that tested the long-term safety and efficacy of aerobic exercise training plus evidence-based medical therapy versus evidence-based medical therapy alone in medically stable outpatients with left ventricular (LV) systolic dysfunction (ejection fraction [EF] Յ35%) and New York Heart Association (NYHA) class II to IV HF. Adult subjects receiving angiotensin-converting enzyme inhibitor and ␤-adrenergic blockade (unless there was documented rationale for variation) for Ն6 weeks were eligible. Exclusion criteria included inability to exercise, regular aerobic exercise (more than once a week), and a major cardiovascular event in the previous 6 weeks. The primary end point was the composite of death or all-cause hospitalization. Death (all-cause) was a prespecified secondary end point. Patients were randomly assigned to usual care alone (optimal medical therapy and a recommendation for regular physical activity) or usual care plus a prescription of 36 sessions of supervised aerobic exercise training at 60% to 70% of heart rate reserve 3 times a week followed by home-based training at the same intensity 5 times a week. Randomization was stratified by center and HF etiology. Participants were followed for a median of 2.5 years.
Data Considerations
Patient characteristics, laboratory values, health status, and physiological parameters at rest and during exercise were collected on standardized forms at baseline and at several points throughout the study. Specific instructions and definitions for all variables were provided to assist sites with form completion.
Statistical Methods
Baseline characteristics were summarized by counts and percentages for categorical variables and by medians with interquartile ranges for continuous variables. For both the primary end point (all-cause death or hospitalization) and the secondary end point (all-cause death), predictive models were developed using a set of 48 candidate variables for possible model inclusion (online-only Data Supplement Table I ). The candidate variables represented a broad range of baseline characteristics, including demographics, medical history, laboratory values, baseline exercise test values, and quality-of-life indices (Kansas City Cardiomyopathy Questionnaire [KCCQ]); however, the candidate variables were restricted to intrinsic patientlevel characteristics (eg, excluding such things as geographic region and use of medications). The aim in developing these predictive models was to provide a useful tool for estimating as accurately as possible the individual patient risk for the given end point.
Although the data were relatively complete for most of the candidate predictor variables, there were several variables with a small number (Ͻ5%) of missing values and 5 variables with more missing data (mitral regurgitation, 8%; creatinine, 10%; sodium, 11%; serum urea nitrogen, 13%; hemoglobin, 24%). To include variables with missing values in the analysis without deleting valuable patient information, the methods of multiple imputation were used. 14 The SAS procedure PROC MI was used to create 5 complete data sets with imputed values to fill in the missing values among candidate predictors. With the 5 completed data sets, the SAS procedure PROC MIANALYZE was used in conjunction with SAS procedure PROC PHREG to develop the predictive risk models. The relationship of each continuous candidate predictor with the outcome of interest was checked for linearity of the log hazard ratio using restricted cubic spline functions. Where relationships were nonlinear, appropriate transformations using piecewise linear splines were used. Two hundred bootstrap samples were obtained from each imputed data set for a total of 1000 bootstrap samples. For each bootstrap sample, a backward selection algorithm was applied with the Cox proportional hazards regression model using a nominal 0.05 critical value for model inclusion. A candidate predictor was included in the model if it met the 0.05 significance level in 75% of bootstrap samples for the primary end point or 60% for the mortality end point. These cutoff values were chosen by examining the optimism-corrected c-indices of various possible cutoff values. 15 The predictor variable relationships with the respective clinical outcomes were descriptively characterized by averaging the Cox model parameter estimates and corresponding 2 statistics across the 5 imputation data sets. Model calibration for the predictive models was assessed by comparing 1-year predicted and observed event rates according to deciles of risk.
Risk scores based on assigning points to various risk factors were developed from the predictive models. For ease of clinical use, these risk scores used a subset of the variables included in the predictive models, termed the simplified predictive models. The subset in each case was obtained through a stepwise process, eliminating at each step the variable that would reduce the c-index the least and continuing until any further reduction would markedly reduce the c-index.
Results
From April 2003 through February 2007, 2331 patients were enrolled in HF-ACTION at 82 centers in the United States, Canada, and France. There were no major differences in baseline characteristics among treatment groups. Over a median follow-up of 2.5 years, 1555 (67%) participants experienced the primary end point, and 387 (17%) experienced the secondary mortality end point. Table 1 shows clinical characteristics for participants with and without events. Median age was 59 years; 28% were women; and 63%, 36%, and 1% had NYHA class II, III, and IV HF, respectively. Blacks comprised 33% of participants. Median LVEF was 25%; ␤-blockade was used in 95% of patients, whereas angiotensin-converting enzyme inhibitors were used in 74% of patients. Participants experiencing the primary composite end point or the secondary mortality end point had a higher median baseline age, a higher median LVEF, and a higher percentage of men and nonwhite race. 
Clinical Predictors of Events in HF-ACTION
The full predictive model for the primary end point (all-cause death or hospitalization) is presented in online-only Data Supplement Table II . The key prognostic factors associated with increased risk of this outcome included measures of performance on the baseline cardiopulmonary exercise (CPX) test (shorter exercise duration and lower peak oxygen consumption [V O 2 ]), measures from the KCCQ, lower values of LVEF, higher values of serum urea nitrogen, the presence of ventricular conduction defects, severe mitral regurgitation, and selected demographics (male sex and nonwhite race). The full predictive model for all-cause mortality is presented in online-only Data Supplement Table III . Several factors from the primary end point model were also highly prognostic in the mortality model (decreased exercise duration, lower LVEF, severe mitral regurgitation, ventricular conduction defects, male sex, and elevated serum urea nitrogen). In addition, other significant factors included body mass index (BMI), serum creatinine, diastolic blood pressure, and angina classification.
The treatment group variable was incorporated into each of the full predictive models, and there was essentially no impact on the coefficients (including hazard ratios) of the other variables. The c-index was virtually unchanged, going from 0.6437 in the without-treatment group to 0.6439 in the with-treatment group in the model for the primary end point. Moreover, adding the treatment group variable did not change the c-index for the mortality model: cϭ0.7357 without treatment, cϭ0.7358 with treatment. The treatment group variable did not improve the predictive ability, nor did it change the estimate of the relationship between the other variables and the outcome variable in each model. Tables 2 and 3 display variables most strongly associated with the primary composite end point and secondary mortality end point, respectively, in the simplified predictive models. The strongest baseline predictor of both the primary and the mortality end points was exercise duration on the CPX test: For every additional minute of exercise duration, there was an associated 8% reduction in risk for the primary end point and an 18% reduction in risk for mortality. The second most important variable for the primary end point predictive model was the KCCQ symptom stability score (in which participants classified their symptoms according to a 5-point Likert scale). This variable consisted of patient response to the following question: "Compared with 2 weeks ago, have your symptoms of heart failure (shortness of breath, fatigue, or ankle swelling) changed?" When compared with the group that indicated no change or had no symptoms, a response of much worse or slightly worse was associated with a hazard ratio of 1.9 (95% CI, 1.6 -2.3), whereas a response of much better or slightly better was associated with a hazard ratio of 1.3 (95% CI, 1.1-1.4). Higher serum urea nitrogen and male sex also were strong predictors of the primary end point. The c-index was 0.63, suggesting a modest capacity of the model to determine which patients are at greatest risk for the hospitalization or death. For the mortality model, higher serum urea nitrogen, male sex, and lower BMI were important determinants of higher mortality in addition to baseline exercise duration. The c-index was 0.73, suggesting moderately good capacity of the model to discriminate patients at greater risk for death.
Clinical Predictors for Simple Risk Score Models
Risk Scores
The multivariable model for the primary end point was converted into a point-based additive risk score (Table 4 ) that included 4 clinical variables. Scores were assigned based on each variable's relative contribution to risk, with a maximum of 100 points possible; the mortality risk score was developed using the same methodology (Table 5 ). Scores were categorized into deciles and used to compare predicted versus observed 1-year risk. As shown in Tables 6 and 7, the risk score allowed discrimination across a wide range of patients, from 21% risk for the primary end point among patients in the first decile (score, 0 -38) to nearly 70% risk among patients in the 10th decile (score, 68 -100) ( Table 6 ). Risk of mortality alone ranged from 1% in the first decile to 14% in patients in the 10th decile ( Table 7 ). The risk score of the primary end point had an optimism-corrected c-index of 0.63, the same as the c-index of the simplified predictive model ( Table 2 ). The risk score for mortality had an optimism-corrected c-index of 0.70, which was slightly less than the c-index of 0.73 for the simplified predictive model for mortality (Table 3) . 
O'Connor et al Predictive Score Model From HF-ACTION
Discussion
To our knowledge, this analysis from the HF-ACTION clinical trial database represents the first risk prediction model for patients with HF due to systolic dysfunction who were treated with a high degree of evidence-based therapy (␤-blockade, 95%; use of an angiotensin-converting enzyme inhibitor, 74%; implantable cardioverter-defibrillator, 40%; biventricular pacing,18%). The risk scores use clinical variables that are readily available for bedside use and encompass a wide range of risks, making this a valuable tool for clinical decision-making. Collectively, these clinical variables were able to discriminate moderately for the primary end point and reasonably well for the mortality end point. Peak exercise capacity as measured by exercise duration during a baseline CPX test was the most important predictor for both the primary end point and the secondary mortality end point in the simplified risk score models developed in this cohort of outpatient ambulatory patients with NYHA class II to IV HF. Exercise duration is highly correlated with peak V O 2 16 and integrates similar physiological information; moreover, it offers the advantages of technical simplicity, wider availability, lower cost, and lower patient burden relative to peak V O 2 .
Previous studies have demonstrated the prognostic value of exercise duration in patients with cardiovascular disease, 17, 18 but information regarding this parameter in ambulatory patients with HF is limited even though recent observational data support the prognostic utility of exercise duration in these patients. 19 However, this utility depends on the adoption of a standardized protocol for comparison among cohorts, such as the Modified Naughton protocol used in the present study. Importantly, determination of exercise duration in this trial occurred with the simultaneous collection and analysis of expired air for determination of the respiratory exchange ratio, a parameter used to avoid termination of an exercise test before peak effort is attained. Finally, recent literature involving prognosis in patients with HF suggests that ventilator efficiency (ie, relationship between volume of air exhaled and volume of CO 2 exhaled [V E/V CO 2 slope]) during exercise is a strong predictor of clinical events in these patients. 20 -22 In our multivariable modeling, exercise duration during baseline CPX testing was a stronger predictor of outcomes than V E/V CO 2 slope and a slightly stronger predictor than peak V O 2 . For this reason, V E/V CO 2 slope and peak V O 2 were not included in the final predictive models.
In the KCCQ, the single question, "Compared with 2 weeks ago, have your symptoms of heart failure changed?" had substantial prognostic value for the primary end point. To our knowledge, this is the first time that a KCCQ symptom domain was observed to carry prognostic information of this magnitude. Any change from stable (better or worse) was associated with an increased risk of cardiovascular events. Previous studies have correlated quality of life with outcomes, including KCCQ. [23] [24] [25] The importance of this finding resides in the simplicity of the question, which can be incorporated into everyday practice, perhaps capturing a part of the medical history or a progressive change in symptoms. The observation that patients who had stable symptoms had better outcomes versus those with recent improvement reflects the benefit of a more consistent course over time.
Consistent with other studies, renal function also was an important predictor of outcomes. 26 -29 Serum urea nitrogen was a stronger predictor of outcome than creatinine level, which accords with previous observations that included patients presenting with acute decompensated HF. 30, 31 The greater prognostic power of serum urea nitrogen may be due to its incorporation of both prerenal and renal function status, a factor incorporated into other predictive models.
Female sex was associated with lower risk of morbidity/ mortality and mortality, as previously observed, 32 but findings have been inconsistent (Table 8 ). Although the mechanism of this sex differential in level of risk is likely complex, it may be related to degree of LV dysfunction and the presence or degree of coronary disease with subsequent amounts of angina, diuretic dosing, renal dysfunction, and BMI. 33 In large cohorts, women with HF are also more likely to have a nonischemic etiology, which may have a better prognosis. Further analyses by sex are warranted.
BMI was inversely related to all-cause mortality, but only for values Ͻ25 kg/m 2 . This finding is consistent with the previous work of Anker et al, 34 suggesting the benefit of higher BMI and detrimental effects of cachexia on mortality. Treatment group (exercise versus usual care) appears in none of the final models because treatment group was not among the strong predictors of either of these end points.
Notably, the present models were developed with a cohort of ambulatory patients with HF with systolic dysfunction, and further study is needed to determine the discriminatory capacity of these models in a patient cohort with severe HF. Gorodeski et al 35 recently applied the Seattle Heart Failure Model to patients with advanced HF undergoing evaluation for an LV assist device or cardiac transplantation. The investigators demonstrated only a modest predictive accuracy (c-index, 0.63-0.68), with substantial underestimation of risk. The addition of brain natriuretic peptide, peak V O 2 , and serum urea nitrogen improved the discrimination of the Seattle Heart Failure Model. This finding has implications for the applicability of our models because serum urea nitrogen is included in the HF-ACTION models.
The development of risk models for ambulatory patients with HF with systolic dysfunction can be helpful for evaluating prognosis at the time of clinical evaluation, although many models have been too complex to be integrated into practice. By developing simple risk scores based on the most important prognostic factors, we have overcome this limitation. For example, a male patient with serum urea nitrogen of 50 mg/dL who is able to tolerate exercise for only 8 minutes and reports feeling worse over the past month would have a high probability (almost 70%) of experiencing a hospitalization or death within the next year and, thus, would likely require aggressive treatment and monitoring.
The HF-ACTION risk scores offer specific advantages over similar models and risk scores. First, the variables were obtained in an outpatient setting from evaluation of clinical characteristics, KCCQ questionnaires, routine laboratory tests, and exercise tests. Second, the risk scores were developed in the setting of evidence-based therapy (use of angioten-sin-converting enzyme inhibition, 74%; use of ␤-blockade, 95%; use of implantable cardioverter-defibrillator therapy, 40%), making them applicable to a broad range of contemporary patients with HF. Third, the cohort studied represents a spectrum of ambulatory patients with HF with reduced EF and NYHA class II to IV symptoms. Finally, the scores incorporate information that, although readily available to HF specialists, has seen only modest prognostic application in patients with less severe HF. Unfortunately, few clinicians routinely use a health status instrument or exercise test data in everyday practice, despite the prognostic potential of these simple assessments.
The current analysis has several limitations. First, although the study cohort is broad, nonambulatory patients and those with preserved systolic function were excluded. On the other hand, these risk scores are the first in our knowledge to include a large cohort of female and black patients. The median age of 59 years, though typical of many clinical HF trials, is considerably younger than the average age of patients with HF in the community. 36 Some variables (eg, N-terminal pro-brain natriuretic peptide) were not obtained in sufficient numbers of patients and were excluded from the analysis. Other potentially important variables were not collected at all (eg, serum uric acid or lymphocyte count, allopurinol use). Exercise duration data measured during CPX testing included a small percentage of patients tested using a cycle ergometer protocol instead of the treadmill protocol used in the majority of patients. Without this mixture of modalities, the association of exercise duration with clinical outcomes might have been even stronger. Although the trial was international in scope, there was only a modest representation of patients from outside the United States, thus limiting the generalizability of these results to non-US patients. Finally, although we used internal validation that incorporated bootstrapping with optimism-corrected c-indexes, this model has not been externally validated in an independent cohort of patients with HF because there are no known similar HF data sets that include peak V O 2 , CPX duration, and KCCQ data. It should also be noted that the optimism-corrected c-indexes were not adjusted to reflect possible additional variability because of the variable selection process used in developing the predictive models.
Ambulatory patients with HF with systolic dysfunction (LVEF Յ0.35) have a high rate of morbidity and mortality despite widespread use of evidence-based therapies. In such patients, simple, easily obtained clinical and laboratory characteristics are important determinants of all-cause hospitalization and all-cause death. The use of predictive risk scores to assess patient risk, both in clinical practice and in clinical trials, may be a powerful tool for treatment decisions for patients with HF with systolic dysfunction.
